Daily Sepsis Research Analysis
Three studies advance understanding of sepsis heterogeneity, metabolism-linked organ injury, and oncology-specific risk. Serial biomarker profiling shows that sepsis endotypes are unstable over hours, challenging single-timepoint classification. Large-scale human data and animal models link lactate and protein lactylation to kidney injury risk, while a nationwide cohort quantifies how cancer type and metastasis shape mortality in sepsis.
Summary
Three studies advance understanding of sepsis heterogeneity, metabolism-linked organ injury, and oncology-specific risk. Serial biomarker profiling shows that sepsis endotypes are unstable over hours, challenging single-timepoint classification. Large-scale human data and animal models link lactate and protein lactylation to kidney injury risk, while a nationwide cohort quantifies how cancer type and metastasis shape mortality in sepsis.
Research Themes
- Temporal instability of biomarker-derived sepsis endotypes
- Lactate and protein lactylation in sepsis-associated acute kidney injury
- Cancer-specific heterogeneity in sepsis mortality risk
Selected Articles
1. Temporal robustness of biomarker-based classification algorithms for sepsis.
In two ICU cohorts with serial 8-hourly biomarker sampling, three immune profiles at admission frequently changed over hours to days. Poor intra-class cohesion (median Rand Index ~65%) indicates that single-timepoint endotyping is unstable, limiting its utility for patient stratification and targeted therapy in sepsis.
Impact: This study challenges the prevailing approach of single-timepoint biomarker endotyping for precision sepsis trials by demonstrating rapid temporal instability. It compels a shift toward longitudinal, time-aware stratification strategies.
Clinical Implications: Avoid relying on single-timepoint immune endotypes for trial enrichment or bedside decisions. Consider repeated biomarker assessments and dynamic models when stratifying patients or timing immunomodulatory therapies.
Key Findings
- Three immune profiles at ICU admission: adaptive activation (A, 43%), hyperinflammatory (B, 17%), and broadly attenuated (C, 39%).
- By 48 hours, prevalence shifted toward the attenuated profile (C increased to 56%).
- Frequent reclassification with poor intra-class cohesion (median Rand Index ~65%), indicating instability of biomarker-derived endotypes.
Methodological Strengths
- High-frequency serial sampling (every 8 hours up to 7 days) across two ICU cohorts
- Latent profile analysis with explicit measures of temporal robustness (transition rates, Rand Index)
Limitations
- Moderate sample size (n=345) and potential cohort-specific biomarker effects
- Biomarker panel limited to 30 immune markers; external validation in broader settings needed
Future Directions: Develop time-aware, dynamic endotyping frameworks and adaptive trial designs that account for rapid immunophenotypic transitions; evaluate whether trajectory-based stratification improves treatment effects.
PURPOSE: Heterogeneity of the host response in sepsis hampers development of effective treatments. Several immunobiologically distinct subphenotypes (or endotypes) have been identified using data-driven analyses of single-timepoint biomarker data, but their temporal stability remains uncertain due to dynamic biology and statistical limitations. METHODS: We analyzed data from 345 sepsis patients across two ICU cohorts. 30 immune biomarkers were measured every 8 h for up to 7 days. Latent profile analysis was used to identify classes upon admission and re-classify patients at later timepoints. Temporal robustness was assessed by (1) inter-class transition rates, and (2) intra-class cohesion (regardless of label) using the Rand Index (RI). RESULTS: At ICU admission, three immune profiles were identified: profile A (149 patients, 43%) reflected adaptive immune activation (elevated IL-4, IL-5, RANTES, and GM-CSF); profile B (60 patients, 17%) a hyperinflammatory state (high IL-6, IL-8, IL-1Ra, and low protein C); and profile C (136 patients, 39%) broadly attenuated inflammation. By 48 h, the prevalences of A and B declined to 31% and 13%, while C increased to 56%. Inter-class transitions occurred most in patients assigned to A (41% of all 8-hourly transitions), compared to 39% and 22% for B and C. Intra-class cohesion across intervals was poor (median RI 65%, IQR 62-64%), indicating that patients classified together at admission did not remain consistently together. CONCLUSION: Sepsis patients were frequently reclassified across immune profiles over short intervals, with approximately one-third of subgroup peers changing at each timepoint. This instability challenges the clinical utility of biomarker-derived endotypes.
2. Lactate and lactylation in sepsis-associated acute kidney injury: clinical evidence from the MIMIC-IV database and mechanistic insights.
In 11,431 ICU sepsis patients, higher admission lactate and lower lactate clearance independently predicted SA-AKI, CRRT use, and mortality, with a nonlinear risk inflection above ~5.7 mmol/L. In CLP mice, kidney-specific protein lactylation increased, suggesting a mechanistic link between lactate metabolism and renal vulnerability.
Impact: Bridging large-scale human data with mechanistic mouse evidence, this work elevates lactate from a perfusion marker to a signaling mediator via lactylation in SA-AKI. It defines actionable thresholds and dynamic metrics (lactate clearance) for risk stratification.
Clinical Implications: Incorporate admission lactate and lactate clearance into SA-AKI risk models and early nephroprotective strategies. Consider monitoring lactylation-related pathways as potential therapeutic targets pending further validation.
Key Findings
- Elevated lactate independently associated with higher SA-AKI risk, CRRT use, and 28-day mortality in 11,431 sepsis patients.
- Restricted cubic spline identified a nonlinear risk increase with an inflection around 5.7 mmol/L.
- CLP mice showed kidney-specific upregulation of protein lactylation, suggesting a mechanistic link to renal injury.
Methodological Strengths
- Large ICU cohort with multivariable Cox models and sensitivity analyses, including RCS for dose-response
- Translational design combining human EHR data (MIMIC-IV) with mechanistic CLP mouse experiments
Limitations
- Observational retrospective design with residual confounding; sepsis phenotyping based on EHR
- Mechanistic lactylation evidence limited to mice; human kidney tissue validation lacking
Future Directions: Validate lactylation signatures in human kidney tissue/urine, test lactate/lactylation-modulating interventions, and integrate lactate dynamics into predictive tools for SA-AKI.
BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) is a common and severe complication of sepsis, yet early predictors remain limited. Lactate, beyond being a marker of tissue hypoperfusion, may act as a signaling molecule through protein lactylation. This study aimed to investigate the association between lactate levels and SA-AKI risk using the MIMIC-IV database and to explore the potential mechanistic role of lactylation in septic mice. METHODS: Adult sepsis patients were identified from the MIMIC-IV (v3.1) database. Patients were stratified by lactate tertiles within 24 h of ICU admission, and lactate clearance (LC) was assessed as a dynamic indicator. The primary outcome was SA-AKI, and secondary outcomes included CRRT use and 28-day mortality. Kaplan-Meier analysis, Cox regression, and restricted cubic spline (RCS) models were performed. In parallel, a murine cecal ligation and puncture (CLP) model was used to evaluate tissue-specific protein lactylation by Western blot, along with serum lactate and hematological parameters. RESULTS: A total of 11,431 patients were included. Higher lactate levels were associated with increased disease severity, higher incidence and severity of SA-AKI, greater use of CRRT, and elevated 28-day ICU and in-hospital mortality. In Cox regression, lactate as both a continuous and categorical variable was independently associated with SA-AKI risk. RCS analysis revealed nonlinear dose-response relationships, with sharply increased risk of SA-AKI above 5.7 mmol/L. In sensitivity analyses ( CONCLUSION: Elevated lactate levels are independently associated with increased risk of SA-AKI in sepsis patients, whereas higher lactate clearance is linked to improved renal outcomes. Moreover, kidney-specific upregulation of protein lactylation in septic mice suggests a possible molecular link between lactate metabolism and renal vulnerability. These findings highlight lactate and lactylation as both prognostic markers and potential mechanistic contributors in SA-AKI.
3. Cancer patients with sepsis: Prognostic insights from a population-based cohort study in Norway.
In a nationwide cohort of 222,832 sepsis admissions, 16.9% had cancer and experienced substantially higher in-hospital mortality, especially with metastatic disease. Relative risks were highest among younger adults, females, and Gram-negative sepsis, emphasizing cancer-type- and metastasis-specific prognostication.
Impact: The study provides precise, population-level estimates of sepsis mortality risk stratified by cancer type, metastasis, age, sex, and pathogen class, directly informing oncology–critical care risk models and resource allocation.
Clinical Implications: Prioritize early aggressive management in metastatic and high-risk cancer subgroups, ensure Gram-negative coverage when appropriate, and integrate cancer-specific variables into sepsis triage and prognostic tools.
Key Findings
- Among 222,832 sepsis admissions, 16.9% had cancer; in-hospital mortality was 16–17% (non-metastatic) vs ~26–27% (metastatic).
- Adjusted RR of death vs non-cancer: non-metastatic 1.39 (men)/1.63 (women); metastatic 2.27 (men)/2.75 (women).
- Risks were highest in younger metastatic patients and in Gram-negative sepsis.
Methodological Strengths
- Nationwide registry with very large sample and 13-year coverage
- Multivariable regression with subgroup analyses by cancer type, metastasis, age, sex, and pathogen class
Limitations
- Administrative coding may misclassify sepsis and cancer status; limited clinical granularity (e.g., SOFA, treatment details)
- Observational design cannot eliminate residual confounding
Future Directions: Integrate clinical severity scores and treatment variables to refine cancer-specific sepsis prognostic models; evaluate targeted pathways for Gram-negative sepsis in oncology populations.
BACKGROUND: Cancer patients with sepsis experience a higher mortality risk than non-cancer patients. However, it remains unclear how this risk varies with cancer type and metastasis status, sex, age, and infecting microbe. METHODS: This nationwide cohort study included all cancer and non-cancer patients ≥18 years hospitalized with sepsis in Norway from 2008 to 2021. Cancer status, sepsis, and hospital mortality were identified from the Norwegian Patient Registry (ICD-10 codes). Multivariable regression analyses estimated absolute and relative risks of hospital mortality across subgroups. RESULTS: Of 222,832 hospitalized sepsis patients, 37,692 (16.9%) had cancer. Hospital mortality was higher in cancer patients, at 16.9% (males) and 16.2% (females) with non-metastatic disease, and 27.1% (males) and 26.2% (females) with metastatic disease. Compared to non-cancer patients, adjusted relative risks RR (95%CI) of hospital death were 1.39 (1.34-1.44, males) and 1.63 (1.55-1.71, females) for non-metastatic cancer, and 2.27 (2.18-2.37, males) and 2.75 (2.62-2.89, females) for metastatic cancer. The type of cancer was a key prognostic factor. The association between cancer and mortality was strongest in metastatic patients under 50 years ((males 40-49 years: RR 5.94 (4.43-7.97), females 18-39 years: RR 8.28 (5.12-13.37), and in those with Gram-negative sepsis. CONCLUSIONS: The increased hospital mortality in cancer patients varied with cancer type and presence of metastasis. The association between cancer and mortality was strongest in females and young adults as well as in Gram-negative sepsis. IMPACT: Knowledge of the specific aspects of sepsis in cancer patients may improve cancer care and guide future research on targeted sepsis therapies.